Src homology 2 (SH2) B adaptor protein 1 (SH2B1) is expressed in various tissues, including the heart. Previous studies have demonstrated that SH2B1 is involved in a variety of biological process, such as maintaining neuronal differentiation, regulating energy and glucose homeostasis, and promoting cell proliferation and motility. However, the role of SH2B1 in cardiac hypertrophy remains unclear. This study aimed at identifying the effects and the underlying mechanisms of SH2B1 in cardiac hypertrophy.
Introduction
Cardiac hypertrophy and heart failure are major causes of high morbidity and mortality in modern societies. 1 Cardiac hypertrophy is not only an adaptive response to physiological and pathological overload, but is also an independent risk factor of major cardiac events. 2 In response to overload, individual cardiac myocytes become mechanically stretched and activate intracellular hypertrophic signalling pathways to re-activate embryonic transcription factors and increase the synthesis of various proteins, such as structural and contractile proteins. 3 -6 However, sustained pathological overload induces maladaptation and cardiac remodelling, resulting in cardiac arrhythmias, diastolic dysfunction, congestive heart failure, and death. 7 -9 Therefore, the suppression of cardiac hypertrophy has emerged as a possible strategy for mitigating pressure overload-induced end-organ damage. It is thus very important to understand the molecular mechanisms that mediate the development of cardiac hypertrophy and the transition to heart failure. Src homology 2 (SH2) B adaptor protein 1 (Adaptor protein with PH and SH2 domains, SH2B1) belongs to an adaptor protein family that also includes SH2B2 (APS) and SH2B3 (Lymphocyte adapter protein, Lnk). 7 All three members share a common domain structure that includes a dimerization domain, a pleckstrin homology domain, several proline-rich regions, and a SH2 domain near the C terminus. 8 SH2B
family members have been implicated in signal transduction processes for several receptor tyrosine kinases and for the Janus kinase (JAK) family of tyrosine kinases. The available evidence suggests that SH2B1 plays critical roles in maintaining neuronal differentiation, regulating energy and glucose homeostasis, and promoting cell proliferation and motility. 9, 10 For example, systemic deletion of SH2B1 results in severe leptin resistance, insulin resistance, obesity, and type 2 diabetes in mice. 11, 12 Additionally, SH2B1 contributes to the malignant progression of tumours, such as those observed in colon, ovary, and non-small cell lung cancers. 13 Importantly, SH2B1 also binds to other adaptor and scaffold protein partners, including the small GTPase protein Rac, Grb2, p130cas, IRS1, and IRS2, 9 and several studies suggest that these proteins are important modulators in signalling pathways and hypertrophy. 10, 14, 15 Notably, SH2B1 is expressed ubiquitously in various tissues, including the heart. 8 These findings indicate that SH2B1 may play an important regulatory role in heart physiology and pathology. Intriguingly, Prudente et al. found that the SH2B1 obesity locus is associated with an increased risk of myocardial infarction (MI) in diabetic patients. 16 However, whether SH2B1 exerts a major role in pressure overload-induced pathological cardiac hypertrophy has not yet been investigated.
Here, we report our finding that SH2B1 was significantly upregulated in heart samples collected from human patients with dilated cardiomyopathy (DCM) or hypertrophic cardiomyopathy (HCM) and from mice after aortic banding (AB). Using gain-and loss-of-function strategies, we found that pressure overload-induced cardiac hypertrophy was exaggerated in SH2B1-overexpressing mice, whereas it was limited in SH2B1-deficient mice. Importantly, similar results were observed in a global SH2B1-knockout rat model. Mechanistically, SH2B1-mediated pro-hypertrophic effects were largely dependent on the positive regulation of JAK2/signal transducer and activator of transcription 3 (STAT3) signalling. In fact, blocking JAK2 with a selective small-molecule inhibitor (TG101348) rescued the adverse effects of SH2B1 overexpression on cardiac hypertrophy. Based on these data, we believe that SH2B1 is a key positive mediator of pathological cardiac hypertrophy and may represent a useful therapeutic target for cardiac hypertrophy.
Methods

Reagents
Antibodies against the following proteins were purchased from Santa Cruz Biotechnology (Dallas, TX, USA): atrial natriuretic factor (ANP; sc20158), b-myosin heavy chain (b-MHC; sc53090), and TG101348 (sc-364740). Antibodies against JAK2 (3230), phospho-JAK2 (3776), phospho-STAT3 (9145), and GAPDH (2118) were purchased from Cell Signaling Technology (Danvers, MA, USA). The anti-SH2B1 antibody (AF6915) was purchased from R&D Systems (Minneapolis, MN, USA). The anti-STAT3 antibody (BS1336) was purchased from Bioworld Technology (Harrogate, UK). The BCA protein assay kit was purchased from Pierce (Rockford, IL, USA). Fetal calf serum (FCS) was ordered from HyClone (Waltham, MA, USA). Cell culture reagents and other reagents were purchased from Sigma (St Louis, MO, USA).
Human heart samples
All procedures involving human tissue samples were approved by the Human Research Ethics Committee of the Renmin Hospital of Wuhan University, Wuhan, China. This study conformed to the principles outlined in the Declaration of Helsinki. Informed consent was obtained from the families of prospective heart donors. Samples of failing human hearts were collected from the left ventricles (LVs) of DCM and HCM patients undergoing heart transplants. 3, 17 Control samples were obtained from the LVs of healthy heart donors who died in accidents, but whose hearts were not suitable for transplantation for non-cardiac reasons.
Study animals
All experiments involving animals were approved by the Animal Care and Use Committee of Renmin Hospital at Wuhan University and confirmed the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (the 8th Edition, NRC 2011). All the mice used were male (C57BL/6J background), aged 8 -10 weeks with body weights of 24 -27 g. All of the animals were housed in an environment with controlled light cycles (12 h light/12 h dark), temperature, and humidity; food and water were provided ad libitum. All of the animal experiments were performed by an experimenter who was blinded to the animals' genotypes.
2.4 SH2B1-knockout and cardiac-specific SH2B1 transgenic mice
) with C57BL/6 × 129 mix background were purchased from the RIKEN BioResource Center (RBRC00994). 18, 19 To obtain the pure C57BL/6 background SH2B1-knockout mice, the SH2B1-knockout mice were crossed with C57BL/6 mice to produce the F1 generation (SH2B1 heterozygous), which was backcrossed with C57BL/6 strain to obtain the F2 generation (SH2B1 heterozygous), and then further backcrossed to the C57BL/6 background until the F9 generation (SH2B1 heterozygous). F9 generation male and female mice were crossed to each other to produce the SH2B1 homozygous knockout (C57BL/6 background) mice. PCR analysis of tail genomic DNA was used to identify the knockout mice using the following primers: primer 1, 5
′ -CTCCAGTGATGTTGTCCTTG-3 ′ ; primer 2, 5
′ -CATCGGGGTAGCATCGGT-3 ′ ; and primer 3, 5 ′ -CAGGAT CTCCTGTCATCTCACCTT-3 ′ . Primers 2 and 3 were used to genotype SH2B1-knockout mice, and primers 1 and 2 were used to genotype wildtype (WT) mice. Transgenic (TG) mice (C57BL/6 background) with cardiac-specific SH2B1 expression were generated by microinjecting the a--MHC-SH2B1 construct into fertilized mouse embryos, which were introduced into pseudopregnant females to obtain the desired TG mice. The TG mice were identified via PCR analysis of tail genomic DNA, and the following primers were used: forward, 5
′ -ATCTCCCCCATAAGA GTTTGAGTC-3 ′ ; reverse, 5 ′ -GAGCTTTGGCTTTGAGGATG-3 ′ . Four independent lines were obtained for SH2B1-TG mice, and each showed a similar phonotype.
SH2B1-knockout rats
A pair of transcription activator-like effector nuclease (TALEN) domains targeting exon 2 of the SH2B1 gene were designed and assembled as previously described. 4 In brief, TALE DNA-binding domains were designed using the online software (https://tale-nt.cac.cornell.edu/node/add/ talen-old) and assembled following 'Unit Assembly'. The TALEN expression plasmids were linearized with PmeI (NEB, R0560L) and transcribed and tailed using the mMessage mMachine T7 Ultra Kit (Ambion, AM1345). Then, these mature mRNAs were purified using the RNeasy Mini Kit (Qiagen, 74104) following the manufacturer's instructions. These purified mRNAs were mixed with injection buffer (10 mM Tris-HCl/0.1 mM EDTA, pH 7.4) to a final concentration of 10 ng/mL mRNA per TALEN arm. Two picolitres of the mixture were injected into the cytoplasm of one-cell-stage embryos under standard conditions. Injected zygotes were transferred into pseudopregnant female rats, and viable pups were obtained. For genotyping, a portion of the SH2B1 gene spanning the TALEN target site was amplified by PCR using the primers SH2B1-F (5
. PCR products or T-A colonies cloned from PCR products were sent for sequencing to allow the identification of editing events.
Aortic banding
AB was performed as previously described. 20, 21 Briefly, mice were anaesthetized intraperitoneally using sodium pentobarbital (50 mg/kg), and the adequacy of anaesthesia was monitored during the surgical procedures using lack of the pedal withdrawal reflex, slow constant breathing, and no response to surgical manipulation. Buprenorphine (0.1 mg/kg, sc) was administered for postoperative analgesia. The left chest of each mouse was opened to identify the thoracic aorta by blunting dissection at the second intercostal space, which was tied against a 26-G needle on the thoracic aorta with a 7-0 silk suture. After ligation, the needle was quickly removed, and the thoracic cavity was closed. Additionally, Doppler analysis was performed to ensure adequate constriction of the aorta. The Doppler probe is placed on the left and right sides of the neck at a 458 angle to detect flow velocities. A Doppler signal processor was used to display Doppler signals.
Only mice with a right carotid/left carotid flow ratio within the 5 -8 range are included for further analysis. Sham-operated mice had an untied ligature placed in the same location. The pressure overload-induced cardiac hypertrophy rat model using constriction of the abdominal aorta at the suprarenal level was established as previously described. 4 The SH2B1-KO rats are Sprague -Dawley (SD) genetic background which is outbred stock. Male rats with 6 weeks old (weighed 200 -250 g) were used in this study. Rats were anaesthetized intraperitoneally using chloralic hydras (300 mg/kg), and then the abdominal aorta was exposed under sterile conditions through a midline abdominal incision. The abdominal aortas were banded against a 22-G needle with a 7-0 silk suture. Finally, Doppler analysis was used to verify adequate constriction of the aorta. A similar procedure without aortic constriction was conducted in the sham group.
Treatment of mice with a JAK2 inhibitor (TG101348)
TG101348 (N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino) pyrimidin-4-ylamino) benzenesulfonamide), a selective smallmolecule JAK2 inhibitor, was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). TG101348 solutions were made in dimethylsulfoxide (DMSO). SH2B1-TG and non-TG (NTG) mice were treated with TG101348 solutions, which were administered by oral gavage twice daily (b.i.d.) at 120 mg/kg for 4 weeks as previously described.
22,23
Echocardiography and haemodynamic evaluation
Echocardiography and haemodynamic measurements were performed as described previously. 24, 25 Mice were anaesthetized with 1.5 -2% isoflurane by inhalation, and then echocardiography was performed to evaluate LV function and structure using a Mylab30CV ultrasound system (Biosound Esaote, Inc.) with a 15-MHz transducer. To measure LV end-systolic dimension (LVESD), LV end-diastolic dimension (LVEDD), and LV fractional shortening, M-mode tracings derived from the short axis of the LV at the mid-papillary muscle level were recorded; parameters were obtained from at least three beats and averaged. For the haemodynamic analysis, a 1.4-Fr catheter-tip micromanometer catheter (SPR-839; Millar Instruments, Houston, TX, USA) was inserted into the LV via the right carotid artery to obtain invasive haemodynamic measurements. A pressure-volume conductance system (MPVS-300 Signal Conditioner, Millar Instruments, Inc.) coupled with a PowerLab/4SP A/D converter was used to record and store the pressure and volume signals continuously, which were then displayed on a computer. The results were analysed with the Chart 5.0 software.
Histological analysis
Mice and rats were anaesthetized intraperitoneally using sodium pentobarbital (100 and 200 mg/kg, respectively), and were sacrificed by swift decapitation according to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health. Hearts were arrested with 1 M KCl and fixed with 10% formalin for .24 h after performing cardiectomies. Then, the hearts were dehydrated, embedded in paraffin, and cut into 5-mm sections. Heart sections were stained with haematoxylin and eosin (H&E) for morphology, picrosirius red (PSR) to identify collagen deposition, or FITC-conjugated wheat germ agglutinin (WGA) to determine the myocyte cross-sectional area (CSA), and then, the sections were visualized by LM. More than 100 LV myocytes were measured in each group. Single myocytes and fibrillar collagen were visualized by microscopy and examined using a quantitative digital image analysis system (Image-Pro Plus 6.0).
Cardiomyocyte culture and infection with recombinant adenoviral vectors
Primary neonatal rat cardiomyocytes (NRCMs) were cultured from the neonatal hearts of 1-to 2-day-old SD rats as previously described. 17, 26 Briefly, SD rats, which were sacrificed by swift decapitation according to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health, that were 1 -2 days of age were euthanized, and cardiectomies were performed. To overexpress SH2B1, full-length rat SH2B1 cDNA under control of the CMV promoter was subcloned into a replication-defective adenoviral vector. AdGFP, a similar recombinant adenovirus-expressing GFP, was used as a control. To knockdown SH2B1, AdshSH2B1 adenoviruses were generated based on three rat shSH2B1 constructs obtained from SABiosciences (KR45212G). The adenoviruses producing the greatest decreases in SH2B1 levels were selected for further experiments. AdshRNA was selected as the non-targeting control. NRCMs were infected with adenovirus for 24 h at a multiplicity of infection of 100. After adenoviral infection, the cells were grown in DMEM/F12 medium containing 20% FCS, BrdU (0.1 mM), and penicillin/streptomycin without serum for 24 h, followed by Ang II (1 mM) treatment for an additional 48 h. For cell surface area measurements, the cells were stained with a-actinin (Sigma) and quantitatively analysed using the Image-Pro Plus software (version 6.0).
Quantitative real-time PCR and western blotting
Quantitative real-time PCR and western blotting were performed as previously described. 3, 6 Total RNA was extracted from animal hearts and primary cells using TRIzol (Invitrogen), and cDNA was generated with the Transcriptor First Strand cDNA Synthesis Kit (Roche). Quantitative RT-PCR was performed using the SYBR Green PCR Master Mix (Roche) to determine the expression levels of our genes of interest, and GAPDH served as the endogenous reference gene.
Western blotting was performed using the extracts from cardiac tissues and cultured cells. The protein concentration was measured using a Pierce w BCA Protein Assay Kit (Pierce). Protein extracts (50 mg) were separated by SDS -PAGE (Invitrogen) and then transferred to a PVDF membrane. Blots were incubated with the indicated primary antibodies overnight at 48C, followed by incubation with a secondary peroxidaseconjugated secondary antibody (Jackson ImmunoResearch Laboratories). Signals were visualized with a FluorChem E System (Cell Biosciences). GAPDH was used as the loading control.
Statistical analysis
Data are represented as means + SD. The two-tailed Student's t-test was used to compare the means of data acquired from human samples, and oneway ANOVA with LSD (assuming equal variances) or Tamhane's T2 (without the assumption of equal variances) tests was used to compare the means of b-MHC, ANP, and SH2B1 expression levels in WT mice, and all other data were statistical analysis with two-way ANOVA with general linear model procedures using a univariate approach. P-values of ,0.05 were regarded as statistically significant. SH2B1 accelerates cardiac hypertrophy 3. Results
SH2B1 expression in human failing hearts and hypertrophic murine hearts
To explore the potential role of SH2B1 in the development of cardiac hypertrophy and heart failure, we first examined whether the SH2B1 expression levels were altered in pathological hearts. Western blot analyses revealed that the protein expression level of SH2B1 was significantly increased in both DCM and HCM human hearts compared with normal donor hearts ( Figure 1A and B) . Accordingly, the increase in SH2B1 expression was accompanied by the up-regulated expression of cardiac hypertrophic markers, such as b-MHC and ANP ( Figure 1A and B). Similarly, in an experimental mouse model of AB-induced cardiac hypertrophy, AB-treated mice exhibited elevated levels of ANP and b-MHC ( Figure 1C ). SH2B1 levels were also significantly upregulated by 2.9-fold in mouse hearts after 4 weeks of AB and by 4.8-fold after 8 weeks of AB compared with sham-operated hearts ( Figure 1C , P , 0.05 vs. sham). Taken together, these results indicate that SH2B1 is involved in the development of cardiac hypertrophy.
SH2B1 modulates Ang II-induced cardiomyocyte hypertrophy in vitro
The observation that SH2B1 expression is increased in response to hypertrophic stimuli indicates that SH2B1 may regulate pathological cardiac hypertrophy. To address this issue, we performed controlled gain-and loss-of-function studies in cultured NRCMs. We infected the cells with either AdshSH2B1 to knockdown SH2B1 or with AdSH2B1 to overexpress SH2B1 ( Figure 2A) ; we then treated these cells with either Ang II (1 mM) or PBS for 48 h and immunostained these cells with a-actinin to allow for cellular size measurement. The results showed that SH2B1 deficiency mediated by AdshSH2B1 infection significantly reduced Ang II-induced cardiomyocyte hypertrophy; in contrast, SH2B1 overexpression by AdSH2B1 remarkably exacerbated cardiomyocyte hypertrophy ( Figure 2B -D) . Consistent with these results, and compared with the controls, the levels of hypertrophic markers (ANP and b-MHC) were markedly decreased following knockdown of SH2B1, but increased following overexpression of SH2B1 in response to Ang II stimulation ( Figure 2E and F ) . Taken together, these in vitro data imply that SH2B1 exerts a detrimental effect on cardiac hypertrophy.
Loss of SH2B1 mitigates pressure overload-induced hypertrophy
Given the evidence indicating a critical regulatory role for SH2B1 in hypertrophic responses in vitro, we sought to evaluate whether reduced SH2B1 levels in the heart could reduce cardiac hypertrophy. To address this hypothesis, we first utilized a mouse model with a global deletion of SH2B1 and subjected these mice to AB or sham operation for 4 weeks. The absence of SH2B1 in mouse hearts was confirmed by immunoblotting ( Figure 3A) . It is important to note that, under basal conditions, SH2B1 2/2 mice manifested no pathological abnormalities in morphometric or contractile functions (data not shown). After 4 weeks of sham or AB, the body weight between SH2B1 2/2 mice and SH2B1
mice did not shown significantly difference (see Supplementary material online, Figure S1A ). However, SH2B1 2/2 mice developed insulin resistance as evidenced by higher fasting blood glucose levels, compromised insulin sensitivity (intraperitoneal insulin tolerance test) and glucose Figure 3E and F) . Accordingly, the mRNA levels of several hypertrophic markers, including ANP, BNP, and b-MHC, were much lower in SH2B1 2/2 mice compared with SH2B1 +/+ mice 4 weeks after AB ( Figure 3G ). Additionally, SH2B1 2/2 mice showed significantly reduced pressure overload-induced cardiac dilation and dysfunction compared with control SH2B1 +/+ mice, as indicated by echocardiographic and haemodynamic parameters (i.e. LVEDD; LVESD; FS%, fractional shortening; EF%, ejection fraction; dP/dt max, maximum rate of pressure increase; and dP/dt min, minimum rate of pressure increase; Figure 3H and I).
To further define the effects of SH2B1 deficiency on maladaptive cardiac remodelling, we examined cardiac fibrosis, a classical feature of the development of pathological cardiac hypertrophy. Paraffinembedded slides were stained with PSR to determine the extent of fibrosis. Both perivascular and interstitial fibrosis were remarkably increased in SH2B1 +/+ hearts subjected to chronic AB, but these features were markedly limited in SH2B1 2/2 hearts ( Figure 3J ). Cardiac fibrosis was further quantified by measuring the collagen volume in the LV and assessing the mRNA levels of known mediators of fibrosis, such as collagen I, collagen III, and connective tissue growth factor (CTGF). We found that the pressure overload-induced fibrotic response was significantly reduced in SH2B1 2/2 mice compared with SH2B1 +/+ mice ( Figure 3K and L) . Collectively, these results provide the first in vivo evidence that loss of SH2B1 in the heart is capable of suppressing the pathological remodelling induced by chronic pressure overload.
SH2B1 overexpression exacerbates pressure overload-induced hypertrophy
Next, we sought to evaluate whether elevation of SH2B1 in the heart would increase pressure overload-induced cardiac remodelling. To address this hypothesis, SH2B1-TG mice were created using the a-MHC AdshRNA or AdGFP/Ang II.
SH2B1 accelerates cardiac hypertrophy promoter. We established four independent germ lines of TG mice (TG1, TG3, TG4, and TG6) and performed western blot analysis to further verify the transgene expression levels ( Figure 4A ). All TG mice were healthy and showed no apparent cardiac morphological or pathological abnormalities (data not shown). We then selected TG line 6 (TG6), which demonstrated the highest level of SH1B1, for the following experiments. To define the consequences of increased SH1B1 expression in hearts with chronic pressure overload, we subjected TG mice and their NTG littermates to AB for 4 weeks. In contrast to the results observed in SH2B1 2/ 2 mice, SH1B1 overexpression aggravated pathological cardiac hypertrophy induced by chronic AB compared with NTG mice, as indicated by the increased HW/BW, HW/TL, and LW/BW ratios ( Figure 4B -D) . Similarly, the cardiomyocyte CSA was significantly increased in AB-induced TG mice compared with NTG mice after 4 weeks of AB ( Figure 4E and F ). Consistent with these data, the expression levels of hypertrophic markers (ANP, BNP, and b-MHC) were much higher in AB-treated TG hearts compared with NTG hearts ( Figure 4G ). SH2B1 overexpression significantly aggravated AB-triggered cardiac dilation and dysfunction, as determined by echocardiographic and haemodynamic measurements ( Figure 4H and I). Furthermore, following chronic AB, TG mouse hearts exhibited increased PSR-positive staining in the interstitial and perivascular spaces and increased collagen volumes compared with control NTG hearts ( Figure 4J and K ). Finally, fibrotic marker analyses consistently demonstrated an increased fibrotic response in AB-treated SH2B1-TG mice compared with AB-treated NTG mice ( Figure 4L ). Taken together, these gain-of-function data indicate that SH2B1 overexpression aggravates cardiac hypertrophy in response to chronic pressure overload.
SH2B1-mediated pathological hypertrophy requires activation of the JAK2 -STAT3 pathway
Given the aforementioned results, we attempted to identify the underlying mechanisms by which SH2B1 exerts its pro-hypertrophic effects. Notably, the cytokine receptor-associated JAK2 was among the first characterized binding partners of SH2B1. 9 Increasing evidence suggests SH2B1 accelerates cardiac hypertrophy that the JAK2/STAT3 pathway is involved in the development of cardiac hypertrophy. 27, 28 Therefore, we sought to examine whether the expression/activity of JAK2/STAT3 is disrupted by up-or down-regulation of SH2B1 in hearts upon chronic pressure overload. Western blot analyses revealed that AB caused significant increases in the levels of phosphorylated JAK2 and STAT3 in SH2B1 +/ + hearts, which were remarkably blocked in SH2B1 2/ 2 hearts after 4 weeks of AB ( Figure 5A) . Similarly, in gain-of-function experiments, we observed that the AB-induced activation of JAK2 and STAT3 was significantly greater in SH2B1-TG hearts compared with NTG hearts ( Figure 5B ).
To further confirm these results in vitro, we decreased or increased SH2B1 expression ex vivo by infecting cultured NRCMs with either AdshSH2B1 or AdSH2B1, followed by treatment with 1 mM Ang II for 48 h. In accordance with the in vivo findings, Ang II-induced activation of JAK2 and STAT3 was reduced in SH2B1-knockdown cells, whereas this activation was promoted in SH2B1-overexpressing cells ( Figure 5C and D) . Taken together, both the in vivo and ex vivo results consistently indicate that SH2B1-mediated pathological cardiac hypertrophy is associated with activation of the JAK2/STAT3 pathway. 
Blocking JAK2 signaling negates SH2B1-mediated detrimental effects on cardiac hypertrophy
The above results indicate that SH2B1 promotes cardiac hypertrophy by activating JAK2/STAT3 signalling. To further validate this notion, we investigated whether the abnormalities observed in TG mice could be reversed by blocking JAK2 with a pharmacological JAK2 inhibitor (TG101348) in vivo following AB. Notably, after 4 weeks of AB, TG101348 treatment significantly reversed the detrimental effects of TG on pressure overload-induced cardiac hypertrophy, as demonstrated by the following: (i) reduced HW/BW, LW/BW, and HW/TL ratios ( Figure 6A-C) ; (ii) reduced gross heart size ( Figure 6D) ; (iii) reduced SH2B1 accelerates cardiac hypertrophy cardiomyocyte CSA ( Figure 6D and E); and reduced cardiac fibrosis ( Figure 6D and F ) in TG101348-treated TG mice compared with vehicle-treated TG mice. Accordingly, treatment of TG mice with TG101348 dramatically improved myocardial structure and function compared with the controls (Figure 6G and H ) . Taken together, these data indicate that pharmacological inhibition of JAK2 negates the cardiac abnormalities observed in SH2B1-overexpressing mice in response to pressure overload.
Absence of SH2B1 in rat hearts alleviates pathological cardiac hypertrophy
Given the profound effects of both the loss and overexpression of SH2B1 in mice during pathological cardiac hypertrophy, we generated a novel SH2B1-knockout rat model using TALEN technology. 4 As shown in Figure 7A , we created a pair of TALEN constructs that specifically targeted SH2B1 exon 2, which lies immediately downstream of the translational start site (codon ATG) in the SH2B1 cDNA sequence. In vitro, linearized TALEN plasmids were transcribed as mature mRNAs, and mixtures of mRNAs from the two TALEN constructs were microinjected into Ntac : SD rat embryos at the single-cell stage. The surviving embryos were then transferred into pseudopregnant females. We then screened all live F0 rats using DNA sequencing and identified the founders with double-peak traces ( Figure 7B ). Subsequently, we backcrossed effective founders to the WT Ntac : SD strain to obtain the F1 generation. Founder #2 -5, which contained an allele with a 1-bp deletion, was selected to establish an SH2B1 rat line ( Figure 7C) . Furthermore, the absence of SH2B1 in the rat hearts was confirmed by western blotting ( Figure 7D) . Notably, at baseline, the SH2B1 2/2 rats did not show any abnormalities in their morphometric or contractile functions (data not shown). Similar to the observations in mice, after 4 weeks of AB, the HW/BW, HW/TL, and LW/BW ratios were significantly reduced in SH2B1 2/ 2 rat hearts compared with SD hearts ( Figure 7E -G) . Additionally, SH2B1 2/2 rat hearts displayed a smaller CSA of cardiomyocytes and less cardiac fibrosis than control SD hearts ( Figure 7H -J ) . Accordingly, cardiac dilation and dysfunction were also improved in SH2B1 2/2 rats compared with SD rats after 4 weeks of AB ( Figure 7K ). Mechanically, we further examined the JAK2 -STAT3 signalling cascade and observed similar results that were similar to the genetic mice experiments in this SH2B1-deficient rat model ( Figure 7L ). Taken together, the findings from this novel SH2B1
2/ 2 rat model, consistent with the findings obtained with established SH2B1 2/ 2 mice, further confirm that SH2B1 is a positive regulator of cardiac hypertrophy in response to chronic AB.
Discussion
SH2B1, a ubiquitously expressed adaptor protein, is a key metabolic regulator, and its function is relatively conserved from insects to humans. 7, 29 However, the functional role of SH2B1 in the development of cardiac hypertrophy and failure has remained unclear. In the present study, we utilized both gain-and loss-of-function approaches to thoroughly decipher the role of SH2B1 in chronic pressure overload-induced cardiac hypertrophy. The major novel findings of this study are as follows: (i) SH2B1 was strikingly elevated in DCM/HCM human hearts and in pressure overload-induced hypertrophic rodent hearts; (ii) SH2B1 deficiency protected hearts against maladaptive hypertrophy, dilatation, and fibrosis in response to chronic pressure overloading, whereas overexpression of SH2B1 accelerated the hypertrophic response of mouse hearts subjected to AB; (iii) the SH2B1-mediated pro-hypertrophic effect was dependent, at least partially, on the regulation of JAK2/STAT3 signalling; and (iv) experiments using the SH2B1-deficient rat model confirmed the findings obtained from the established mouse model. Collectively, our study, for the first time, suggests that SH2B1 is an intrinsic positive regulator of pressure overload-induced cardiac hypertrophy, and that SH2B1 may represent a novel therapeutic target for the treatment of pathological cardiac hypertrophy. SH2B1, a SH2 domain-containing adaptor, binds to numerous protein tyrosine kinases, including both cytoplasmic tyrosine kinases (e.g. JAK1, JAK2, and JAK3) and receptor tyrosine kinases (e.g. the receptors for insulin, IGF-1, PDGF, FGF, nerve growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor). 8 Once activated, SH2B1 may elicit diverse, individual responses to a particular signal that are dependent on its interacting partners. Therefore, the possible mechanisms by which SH2B1 regulates cardiac hypertrophy may also be associated with its binding partners. The cytokine receptor-associated JAK2 was among the first characterized binding partners of SH2B1 in a yeast two-hybrid screen. 30 The primary JAK2-binding site for the SH2 domain of SH2B1 has been identified as phosphotyrosine 813 (pTyr813), which resides in a YXXL motif in a region adjacent to the kinase domain. 31, 32 In cultured cells, SH2B1 is not only tyrosyl phosphorylated by JAK2 but also potentiates JAK2 activation, which subsequently activates STAT transcription factors. 33, 34 Previous studies demonstrated that JAK2/STAT3 signalling plays a critical role in cardiac pathophysiology, but its roles varied under different stimulations and models. Generally, STAT3 signalling is thought to be cardioprotective under ischaemia/reperfusion stress. Negoro et al. 35 reported that activation of STAT3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the up-regulation of manganese superoxide dismutase. Oshima et al. 36 showed that activation of STAT3 protects myocardium from ischaemia/reperfusion injury through metallothionein induction in the heart. Hilfiker-Kleiner et al. 37 To demonstrate physiological function of STAT3, Kunisada et al.
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generated cardiac-specific STAT3 TG mice, which exhibited marked ventricular hypertrophy. In the present study, to elucidate the molecular mechanisms involved in SH2B1-mediated pro-hypertrophic effects, we examined the status of the JAK2/STAT3 signalling cascade in our hypertrophic models. Interestingly, we found that activation of both JAK2 and STAT3 in response to chronic pressure overload or Ang II stimulation was almost completely blocked by SH2B1 deficiency, but greatly enhanced by cardiac-specific overexpression of SH2B1. These findings in vitro and in vivo suggest that SH2B1 exerts its prohypertrophic effects through the promotion of JAK2/STAT3 signalling. Such findings are consistent with a previous study, showing that SH2B1 acts as an enhancer of JAK2/STAT3 activity in leptin signalling. 41 In fact, inactivation of JAK2 by a pharmacological JAK2 inhibitor negated the pro-hypertrophic effects of SH2B1 on cardiac hypertrophy. Thus, we believe that the detrimental effects of SH2B1 on cardiac hypertrophy are dependent, at least partially, on activation of the JAK2/STAT3 cascade. In this study, cardiac SH2B1 expression was remarkably up-regulated not only in AB-treated mouse hearts, but also in the hearts of human DCM or HCM patients. Meanwhile, we observed that the loss of SH2B1 suppressed AB-induced cardiac hypertrophy, indicating that blockade of SH2B1 might represent a new strategy for treating hypertrophic heart disease, which deserves additional investigation and validation. It should be pointed out that although reduced cardiac hypertrophy was observed in SH2B1-knockout mice at 4 weeks after AB compared with WT, whether this cardioprotective effect could be retained longer time (8 weeks after AB) needs further study. In addition, further studies will be necessary to investigate the regulatory mechanisms of SH2B1 expression in the heart.
SH2B1 accelerates cardiac hypertrophy
Previous studies suggest that SH2B1 plays a critical role in regulating energy and glucose homeostasis, which have a potential impact on cardiac pathological response. Rui and his colleagues 8,11,12,42 -46 reported that SH2B1-knockout mice have severe dysbolismus, including obesity, hyperleptinaemia, hyperlipidaemia, hyperglycaemia, hyperinsulinaemia, and hepatic steatosis. On the contrary, convincing results reported by Yoshimura and colleagues 47 demonstrated that unlike the C57BL/6 × 129 mixed background, SH2B1-knockout mice have growth retardation, lower body weight, and white adipose tissue after breeding them on the C57BL/6 background. As Yoshimura and colleagues have discussed in the discussion part of their published paper, the disparity between their results and the observations reported by Rui and his colleagues may be due to the genetic background of mice or housing conditions. Actually, Rui and colleagues 12 also observed growth retardation in young SH2B1-KO mice and progressively gained body weight after 7 weeks of age. On the other hand, Rui and his colleagues observed that SH2B1-KO mice gained relatively less body weight than their WT littermates when housed individually and pair-fed. They explained that this phenomenon was most likely due to increased energy expenditure in SH2B1-KO mice. 12 Similarly, Ohtsuka et al. 18 showed that SH2B1-KO mice have less body weight at 2 -6 weeks of age, and then grow faster and have similar body weight as WT mice at 10 weeks of age. Ren et al. 12 demonstrated that AgRP, which may inhibit the melanocortin system in the hypothalamus to increase the sensitivity to stress and stress-induced weight loss, was significantly increased its expression level in SH2B1-KO mice. In the present study, SH2B1-KO mice were subjected to AB or sham operation at 8 -10 weeks of age (weighted 24 -27 g), and then kept for more 4 weeks. Similar to Ohtsuka's publication, the body weight of SH2B1-KO mice has no significant difference with WT mice at 8 -10 weeks of age. Furthermore, we did not observe significantly difference in body weight between WT and SH2B1-KO mice 4 weeks after AB or sham surgery, which may due to surgical intervention stimulation and increased AgRP expression. In accordance with previous publications, SH2B1-KO mice, in the present study, developed insulin resistance, but it has not yet led to changes in cardiac structure and heart function 4 weeks after sham operation. Moreover, SH2B1-KO mice displayed well cardiac protection after 4 weeks of AB ( Figure 3H and I ). Thus, in the present study, insulin resistance elicited by SH2B1 knockout did not exert important impact on cardiac phenotype during a short-term surgical intervention. Interestingly, SH2B1 expression was down-regulated in the hypothalamus in high-fat-fed diet rats, whereas SH2B1 expression was significantly increased in the hypothalamus of high-fat-fed mice. 48, 49 Therefore, it is tempting to speculate that, in different animal models, SH2B1 could serve similar or different regulatory roles in cardiac hypertrophy upon stress. Notably, because the physiological characteristics of rats are similar to those of humans, the rat may provide a useful model for studies of the cellular and behavioural effects of cardiovascular diseases, including hypertension, MI, and heart failure. 50, 51 Importantly, genome-editing technologies such as designer TALENs permit targeted genome modifications in rats and can be designed to target any DNA sequence. 52 Thus, we successfully established a SH2B1-knockout rat model by utilizing TALENs in the SD rat background. More importantly, the results obtained from SH2B1 2/ 2 rats were consistent with our SH2B1 2/ 2 mice in terms of their responses to pressure overload. To our knowledge, this is the first report describing the use of the TALEN technology to create SH2B1 2/2 rats, and our findings highlight the role of SH2B1 as a novel positive modulator of pathological cardiac hypertrophy in both mice and rats.
In conclusion, our results identify an important role for SH2B1 in mediating pressure overload-induced cardiac hypertrophy and remodelling. Mechanistically, the pro-hypertrophic effects elicited by SH2B1 were associated with the activation of JAK2/STAT3 signalling. These novel findings advance our understanding of the molecular mechanisms underlying pressure overload-triggered cardiac remodelling and may provide a new target for the treatment of pathological cardiac hypertrophy.
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